Literature DB >> 20160494

Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase.

Samuel McNeely1, Chiara Conti, Tahir Sheikh, Himali Patel, Sonya Zabludoff, Yves Pommier, Gary Schwartz, Archie Tse.   

Abstract

Checkpoint kinase 1 (Chk1) regulates cell cycle checkpoints and DNA damage repair in response to genotoxic stress. Inhibition of Chk1 is an emerging strategy for potentiating the cytotoxicity of chemotherapeutic drugs. Here, we demonstrate that AZD7762, an ATP -competitive Chk1/2 inhibitor induces gammaH2AX in gemcitabine-treated cells by altering both dynamics and stability of replication forks, allowing the firing of suppressed replication origins as measured by DNA fiber combing and causing a dramatic increase in DNA breaks as measured by comet assay. Furthermore, we identify ATM and DNA-PK, rather than ATR, as the kinases mediating gammaH2AX induction, suggesting AZD7762 converts stalled forks into double strand breaks (DSBs). Consistent with DSB formation upon fork collapse, cells deficient in DSB repair by lack of BRCA2, XRCC3 or DNA-PK were selectively more sensitive to combined AZD7762 and gemcitabine. Checkpoint abrogation by AZD7762 also caused premature mitosis in gemcitabine-treated cells arrested in G(1)/early S-phase. Prevention of premature mitotic entry via Cdk1 siRNA knockdown suppressed apoptosis. These results demonstrate that chemosensitization of gemcitabine by Chk1 inhibition results from at least three cellular events, namely, activation of origin firing, destabilization of stalled replication forks and entry of cells with damaged DNA into lethal mitosis. Additionally, the current study indicates that the combination of Chk1 inhibitor and gemcitabine may be particularly effective in targeting tumors with specific DNA repair defects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20160494     DOI: 10.4161/cc.9.5.10935

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  43 in total

Review 1.  Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?

Authors:  Tetyana V Bagnyukova; Ilya G Serebriiskii; Yan Zhou; Elizabeth A Hopper-Borge; Erica A Golemis; Igor Astsaturov
Journal:  Cancer Biol Ther       Date:  2010-11-01       Impact factor: 4.742

2.  Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.

Authors:  Neil Beeharry; Eugenia Banina; James Hittle; Natalia Skobeleva; Vladimir Khazak; Sean Deacon; Mark Andrake; Brian L Egleston; Jeffrey R Peterson; Igor Astsaturov; Timothy J Yen
Journal:  Cell Cycle       Date:  2014-06-23       Impact factor: 4.534

Review 3.  More forks on the road to replication stress recovery.

Authors:  Chris Allen; Amanda K Ashley; Robert Hromas; Jac A Nickoloff
Journal:  J Mol Cell Biol       Date:  2011-02       Impact factor: 6.216

4.  ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.

Authors:  Catherine J Huntoon; Karen S Flatten; Andrea E Wahner Hendrickson; Amelia M Huehls; Shari L Sutor; Scott H Kaufmann; Larry M Karnitz
Journal:  Cancer Res       Date:  2013-04-02       Impact factor: 12.701

5.  Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776.

Authors:  Carl G Engelke; Leslie A Parsels; Yushen Qian; Qiang Zhang; David Karnak; Jordan R Robertson; Daria M Tanska; Dongping Wei; Mary A Davis; Joshua D Parsels; Lili Zhao; Joel K Greenson; Theodore S Lawrence; Jonathan Maybaum; Meredith A Morgan
Journal:  Clin Cancer Res       Date:  2013-06-26       Impact factor: 12.531

6.  Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.

Authors:  Leslie A Parsels; Yushen Qian; Daria M Tanska; Marisa Gross; Lili Zhao; Maria C Hassan; Sankari Arumugarajah; Joshua D Parsels; Linda Hylander-Gans; Diane M Simeone; Deborah Morosini; Jeffrey L Brown; Sonya D Zabludoff; Jonathan Maybaum; Theodore S Lawrence; Meredith A Morgan
Journal:  Clin Cancer Res       Date:  2011-04-11       Impact factor: 12.531

7.  ATR kinase regulates its attenuation via PPM1D phosphatase recruitment to chromatin during recovery from DNA replication stress signalling.

Authors:  Debadrita Bhattacharya; Disha Hiregange; Basuthkar J Rao
Journal:  J Biosci       Date:  2018-03       Impact factor: 1.826

8.  Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762.

Authors:  Sheena M Aris; Yves Pommier
Journal:  Cancer Res       Date:  2011-12-21       Impact factor: 12.701

Review 9.  Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies.

Authors:  Thomas P Matthews; Alan M Jones; Ian Collins
Journal:  Expert Opin Drug Discov       Date:  2013-04-18       Impact factor: 6.098

Review 10.  The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design.

Authors:  Ruth Thompson; Alan Eastman
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.